An opportunity in adversity... - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

An opportunity in adversity...

Apr 3, 2000

Glaxo India is the 51% subsidiary of the world's largest pharmaceutical company Glaxo-Wellcome Plc. The 8 bn parent has proposed a merger with Smithkline Beecham which is expected to be in place by July 2000.

Glaxo India has equally impeccable credentials. A presence in a large number of therapy areas (over 60% of the market), a market leader in 80% of the segments in which the company operates and a large portfolio of over 200 product packs. Besides, the company enjoys the trust of the medical profession. Its prescription brands such as Betnovate (dermatologicals), Zinetac (ranitidine), Becadexamin (vitamin) Cetzine (anti-histamine) are as well known as over the counter products in their own rights. The company has a clean balance sheet and a first class management.

The company however seems to be caught in a cleft stick. Not of its own making though.

First, of all the Indian pharmaceutical formulations market itself has slowed with growth down to single digits of around 7-8%. This was primarily since antibiotics, vitamins and cough and cold remedies dominate the Indian market with almost one-third share and a slowdown in these has led to an overall slowdown. Glaxo has bettered the market though with an almost 11% growth.

What the company has been battling with is the after effects of the rampant trade offers and price cutting, which its competitors are making. This would imply that any stockist/wholesaler who would normally stock drugs for around 15-20 companies would have built up relatively higher stock levels reducing the primary sales to a trickle. Besides, quite a few companies have been offering competing products in the non-branded generic market which are discounted for the trade at much higher levels than for the consumers.

The second major leash for the topline growth is the fact that the company derives almost 60% of its revenues from products under price control. Some of its major brands such as Zinetac and the Betnovate range are under price control and the management does not envisage a wholesale modification to the drug price control order in the near future.

Another factor holding back both topline and bottomline growth is the delay in the legal merger of Burroughs Wellcome (BWIL). Glaxo has not been able to consummate this, as the staff at BWIL's Mulund plant has refused to accept Glaxo's lower wage scales. BWIL has a much older portfolio of products than Glaxo but since most of it is out of price control the company reports better return ratios than Glaxo. However, a legal merger with Glaxo seems to be still sometime away.

Glaxo's recent results are reflective of these factors. The company has registered a 11% fall in the net profit (to Rs 770 million) despite the increase in the topline by around 11% (to Rs 8555 million).

(Rs m) CY99 CY98
Net Sales 8,855.0 7,938.4
Other Income 452.1 347.8
Profit on sale of property 218.7 195.0
Total expenditure 8,215.2 7,052.7
Interest 99.0 86.3
Depreciation 162.1 141.9
PBT 1,049.5 1,200.3
Tax 278.9 334.0
PAT 770.6 866.3
Equity 597.8 597.8

However, is one were to judge the company's performance in the light of the industry slowdown it is actually quite creditable. The company's costs increased during the year due to the increase import duty of its imported bulk drug cefuroxime axetil. This bulk drug is used for the manufacture of Ceftum, an antibiotic, which contributes around 4.5% of the company's turnover. This is the reason for the decline in the profits. The coming year is however expected to be better. For one, the company is likely to benefit to the extent of the around Rs 80 million from the upward revision in the prices of the Betamethasone range in the current year.

Glaxo's growth in the future could be driven by its impending amalgamation with SmithKline. As far the Indian operations are concerned the merged company with a market share of 7% will be way ahead of competitors Cipla and Ranbaxy. The merged company will have brands such as Iodex, Augmentin (an amoxycillin-clavulanic acid combination), Engerix (Hepatitis B vaccine), Zevit and Livogen (vitamins and minerals), which will complement its prescription led product profile. The merged entity will also command an enviable marketing network that will go a long way in its attempt to increase market share.

Glaxo has posted a mixed performance over the last two year's. However, the pending mergers with Burroughs Wellcome and SmithKline Beecham and its recent attempts to restructure its operations have the potential to rev up its performance in the coming year's.

Equitymaster requests your view! Post a comment on "An opportunity in adversity...". Click here!


More Views on News

GSK PHARMA Announces Quarterly Results (2QFY21); Net Profit Down 84.8% (Quarterly Result Update)

Oct 30, 2020 | Updated on Oct 30, 2020

For the quarter ended September 2020, GSK PHARMA has posted a net profit of Rs 765 m (down 84.8% YoY). Sales on the other hand came in at Rs 9 bn (down 0.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 2.2% (Quarterly Result Update)

Aug 26, 2020 | Updated on Aug 26, 2020

For the quarter ended June 2020, GSK PHARMA has posted a net profit of Rs 1 bn (down 2.2% YoY). Sales on the other hand came in at Rs 6 bn (down 17.7% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

More Views on News

Most Popular

This One Smallcap Stock is a Must Have in Your Portfolio (Profit Hunter)

Nov 11, 2020

Investing in this smallcap could open doors of huge, long-lasting wealth.

This Diwali Consider Richa's #1 Stock Pick for 2021 (Profit Hunter)

Nov 13, 2020

Why I admire the approach that Richa uses to zero in on stocks with huge upside potential.

Should You Buy Gold Now? (Fast Profits Daily)

Nov 11, 2020

Pfizer has announced a vaccine for covid-19. In response, gold prices have fallen. Should you buy? Find out in this video..

Don't Let Brokerages Fool You into Buying HUL & Nestle. The Real Money is in These Stocks Right Now... Views On News (Views On News)

Nov 12, 2020

Rahul Shah discusses why he preferred a little known stock over Nestle Ltd and how he was proven right.

US Elections: Won a Battle, Now the War (The Honest Truth)

Nov 13, 2020

Ajit Dayal on the urgent need to fix the disparity between the rich and the poor in the US.


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms


Nov 24, 2020 03:36 PM


  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks